Australia's Telix Pharmaceuticals slides on sequential fall in quarterly revenue

** Shares of Australia's Telix Pharmaceuticals TLX.AX fall 7.6% to A$14.56, hitting their lowest level since August 5

** The radiopharmaceutical company reported a 1% sequential fall in group revenue for the third quarter to $235 million, though this was an increase compared to last year

** Revenue from its biggest segment precision medicine was stagnant, compared with previous quarter at $201 million

** "We expect some seasonality and our 2H forecasts imply 4Q will rise again, against the backdrop of a maturing market in existing indications," says Citi

** Telix stock up over 30%, YTD